

# **The Expansion Thesis: Structural Validation of the Diagnostic Complexity Crisis in Solid Tumor Oncology**

## **Executive Summary**

The central premise of the "Expansion Thesis" is that the oncology diagnostics market is undergoing a phase transition from a consolidated, phenotype-based discipline to a hyper-expanded, genotype-based ecosystem. This transition is not linear; it is exponential, driven by a fundamental decoupling of disease taxonomy from microscopic morphology. As the definition of cancer fractures into hundreds of molecularly distinct orphan diseases, the cognitive and operational load required to diagnose and treat a single patient has exceeded the capacity of unassisted human workflows. This report validates the Expansion Thesis by conducting an exhaustive analysis of the 2021 World Health Organization (WHO) reclassification of Thoracic and Central Nervous System (CNS) tumors—the two most significant drivers of diagnostic complexity in modern oncology.

The analysis confirms that the "molecularization" of taxonomy has created a mandatory expansion of the diagnostic funnel. In the thoracic domain, the near-elimination of "Large Cell Carcinoma" necessitates a universal application of immunohistochemistry (IHC) and comprehensive genomic profiling (CGP) to resolve lineage, effectively expanding the addressable market for diagnostic inputs per patient. Simultaneously, in the CNS domain, the redefinition of Glioblastoma via strictly molecular criteria (IDH, TERT, EGFR) has rendered traditional histological grading insufficient, forcing a 100% penetration of molecular diagnostics for diffuse gliomas.

Crucially, this report identifies a secondary "Expansion" that creates the venture opportunity: the expansion of operational overhead. The fragmentation of diagnosis has precipitated a crisis in the Multidisciplinary Molecular Tumor Board (MTB), where the "time tax" of manual data integration now threatens the financial viability of precision medicine programs. Through detailed economic modeling and case study analysis of the emerging software infrastructure—specifically platforms like Roche Navify, Syapse, and GenomOncology—we demonstrate that the only solution to this complexity crisis is the deployment of enterprise-grade Clinical Decision Support (CDS) systems. The Expansion Thesis is therefore validated not just by biological imperative, but by economic necessity.

## **Section 1: The Molecular Tsunami – Redefining the Taxonomy of Thoracic Malignancies**

The validation of the expansion thesis finds its strongest evidence in the transformation of thoracic oncology. Lung cancer, historically treated as a monolith or a simple binary of "Small Cell" versus "Non-Small Cell," has been atomized. The 2021 WHO Classification of Thoracic Tumours (5th Edition) represents a watershed moment in pathology, effectively mandating the molecular expansion of the diagnostic workflow. The era of "Lung Cancer" as a generic diagnosis is over; the field has entered an era of hyper-fragmentation where histological ambiguity is no longer clinically acceptable and "Not Otherwise Specified" (NOS) diagnoses are viewed as failures of the diagnostic process.

### **1.1 The Death of "Large Cell Carcinoma": A Case Study in Market Expansion**

For decades, "Large Cell Carcinoma" (LCC) served as a diagnostic catch-all for Non-Small Cell Lung Cancers (NSCLC) that lacked clear features of adenocarcinoma (glandular differentiation) or squamous cell carcinoma (keratinization). It was a diagnosis of exclusion—a "wastebasket" category that allowed pathologists to categorize undifferentiated tumors without advanced testing. In previous eras, this distinction mattered little, as the therapeutic options—platinum-based chemotherapy—were identical regardless of subtype.

The 5th Edition WHO classification has fundamentally dismantled this category, driving a massive expansion in the requirement for ancillary testing. The new guidelines stipulate that a diagnosis of LCC can only be made on **resected** tumors that lack any clear morphologic or immunohistochemical differentiation.1 This is a critical distinction because the vast majority of lung cancer diagnoses (approximately 70%) occur on **small biopsies** or cytology specimens, not resections.2 Therefore, the diagnosis of LCC is effectively prohibited in the setting where most cancer is detected.

#### **1.1.1 The Mandatory IHC Panel and Reclassification Dynamics**

This shift necessitates a mandatory expansion of the diagnostic workup. Pathologists can no longer rely on Haematoxylin and Eosin (H\&E) staining alone. To comply with WHO 2021 standards, any NSCLC that does not show obvious differentiation must undergo immunohistochemical (IHC) staining to attempt to drive it into a specific lineage category.4 This effectively expands the "minimum viable product" for a lung cancer diagnosis from a single H\&E slide to a multi-slide IHC panel.

The required markers for this lineage resolution are specific and non-negotiable. For adenocarcinoma differentiation, Thyroid Transcription Factor-1 (TTF-1) and Napsin A are the standard bearers. Conversely, for squamous differentiation, p40 is now the preferred marker over p63 due to its higher specificity, often paired with CK5/6.6 The nuance here is critical: p63 is sensitive but can stain adenocarcinomas, leading to false positives, whereas p40 is highly specific for squamous lineage. The WHO 2021 guidelines explicitly push for p40 to reduce misclassification.6

The implication for the expansion thesis is direct: every undefined lung tumor now triggers a revenue event for diagnostic reagents and, crucially, adds a data layer to the patient record. Studies indicate that rigorous application of these markers reclassifies the vast majority of tumors that would have historically been called "Large Cell Carcinoma." Research utilizing these panels demonstrates that approximately **90% of LCCs are reclassified** upon further scrutiny.7

The redistribution of these diagnoses is not random. Approximately 60% to 70% of these undifferentiated tumors reclassify as **Adenocarcinoma** (specifically the solid variant), while roughly 10% to 20% reclassify as **Squamous Cell Carcinoma** (non-keratinizing variant).8 A smaller fraction, approximately 5%, are identified as **Large Cell Neuroendocrine Carcinoma (LCNEC)**, a particularly aggressive high-grade malignancy.9 Only a vanishingly small fraction remain as "LCC-Null" or true Large Cell Carcinoma.

This "disappearance" of LCC is not a reduction in disease, but an **expansion of precision**. By forcing these tumors into the Adenocarcinoma or Squamous categories, the WHO guidelines expand the pool of patients eligible for molecular targeted therapies. Adenocarcinomas are the primary reservoir for actionable driver mutations (*EGFR, ALK, ROS1*), whereas LCCs were historically treated with generic chemotherapy. This reclassification expands the Total Addressable Market (TAM) for downstream Next-Generation Sequencing (NGS), as a reclassified adenocarcinoma immediately qualifies for broad-panel testing that an LCC might not have received in a conservative reimbursement environment.

### **1.2 The "NSCLC-NOS" Problem and the Tissue Stewardship Crisis**

The WHO 2021 classification introduces a section entirely dedicated to the classification of **small diagnostic samples**.2 This acknowledges the clinical reality that most patients are diagnosed via needle biopsy, where tissue is scarce and precious.

The term **"NSCLC-NOS"** (Non-Small Cell Lung Cancer, Not Otherwise Specified) is now strictly defined as a "use as last resort" operational term for small biopsies where IHC is inconclusive or tissue is exhausted. It is **not** a distinct biological entity.4 The WHO guidelines and the International Association for the Study of Lung Cancer (IASLC) emphasize that "NSCLC-NOS" should be minimized as much as possible because it leaves the treating oncologist in a therapeutic blind spot. Pemetrexed, a standard-of-care chemotherapy, is effective in non-squamous histology but potentially toxic or ineffective in squamous cases; thus, a diagnosis of "NOS" precludes the safe use of this drug, limiting patient options.11

The Tissue Stewardship Crisis:  
The expansion of diagnostic requirements creates a severe logistical crisis known as "tissue stewardship." The same small biopsy must now support an ever-expanding list of interrogations:

1. **Morphological diagnosis** (H\&E) to confirm cancer.  
2. **IHC subtyping** (TTF-1, p40) to resolve the LCC/NOS ambiguity.  
3. **Predictive IHC** (PD-L1) for immunotherapy eligibility, which is now a standard reflex test.12  
4. **Molecular Profiling** (NGS) for targeted therapy, requiring significant DNA input.14

This competition for tissue volume validates the need for **Liquid Biopsy** integration and, more importantly, sophisticated **Informatics Platforms** (software) to manage the workflow. If a pathologist wastes tissue on excessive IHC to prove a subtype (e.g., using 6 stains when 2 would suffice), they may render the sample "QNS" (Quantity Not Sufficient) for NGS, denying the patient life-saving targeted therapy. This delicate balance requires "Integrated Diagnostic Reporting"—a core component of the expansion thesis, where software coordinates the prioritization of tests to ensure that the limited biological capital of the biopsy is spent on the highest-yield questions.15

### **1.3 Molecular Subtypes: The Fragmentation of Adenocarcinoma**

The WHO 2021 classification cements the transition of Lung Adenocarcinoma from a single disease entity into a cluster of molecularly defined orphan diseases. This fragmentation is the primary engine of the expansion thesis in therapeutics and diagnostics.

The "Must-Test" Expansion:  
In 2015, testing was largely limited to EGFR and ALK. The 2021 update and subsequent National Comprehensive Cancer Network (NCCN) guidelines have expanded the "essential" biomarker list dramatically.14 We have moved from a "one-gene, one-drug" model to a broad-panel necessity.

* **Tier 1 (Standard of Care):** Testing is now mandatory for *EGFR* (sensitizing mutations \+ exon 20 insertions), *ALK* fusions, *ROS1* fusions, *BRAF* V600E mutations, *NTRK* fusions, *MET* exon 14 skipping mutations, *RET* fusions, and *KRAS* G12C mutations.13  
* **Emerging/Tier 2:** The pipeline continues to expand with *HER2* (ERBB2) mutations, *neuregulin* (NRG1) fusions, and negative predictors like *SMARCA4*, *STK11*, and *KEAP1*.

Diagnostic Drift and "Gene-First" Diagnosis:  
We are witnessing "Diagnostic Drift" where the molecular signature overrides the histological appearance. For example, the recognition of Thoracic SMARCA4-deficient undifferentiated tumor as a distinct entity in the WHO 2021 classification.4 This is a high-grade tumor that can morphologically mimic a carcinoma or a sarcoma but is defined by the loss of the SMARCA4 gene (detected via IHC or sequencing). Without specific testing for SMARCA4 loss, this aggressive tumor is invariably misdiagnosed, leading to ineffective treatment. Similarly, NUT carcinoma and Bronchiolar Adenoma (ciliated muconodular papillary tumor) represent new entities defined by molecular or specific immunophenotypic features that require specialized knowledge to identify.4  
**Conclusion for Expansion Thesis (Thoracic):** The WHO 2021 changes in lung cancer have effectively outlawed ambiguity. By mandating the resolution of "Large Cell Carcinoma" and creating a roster of molecularly obligatory targets, the guidelines have expanded the complexity of every single lung cancer case. A diagnosis now requires the integration of Morphology, IHC, and NGS. This "Multi-Modal" data stream cannot be managed on paper; it requires the software infrastructure our thesis predicts.

---

## **Section 2: The CNS Paradigm Shift – The Molecular Redefinition of Glioblastoma**

If the changes in lung cancer represent an *evolution* toward complexity, the changes in Central Nervous System (CNS) tumor classification represent a *revolution*. The 2021 WHO Classification of Tumors of the Central Nervous System (WHO CNS5) fundamentally breaks the century-old reliance on histology for grading, validating the expansion thesis by introducing the concept of **"Molecular Glioblastoma."**

### **2.1 The Schism: IDH-Mutant vs. IDH-Wildtype**

The most profound change in CNS5 is the strict separation of adult diffuse gliomas based on **Isocitrate Dehydrogenase (IDH)** mutation status.21 This is not a subtle refinement; it is a taxonomic divorce.

In the pre-2021 era (WHO 2016), "Glioblastoma" was a morphological bucket that included both IDH-wildtype (primary) and IDH-mutant (secondary) tumors. They were grouped together based on shared histological features of necrosis and microvascular proliferation. The WHO 2021 classification radically alters this. The term **Glioblastoma** is now *exclusively* reserved for **IDH-Wildtype** tumors.23

Any tumor that is IDH-Mutant is now classified as an **Astrocytoma, IDH-mutant**, even if it possesses necrosis and looks identical to a Glioblastoma under the microscope.21 These IDH-mutant tumors are subsequently graded as CNS WHO Grade 2, 3, or 4\. Consequently, a diagnosis of "Secondary Glioblastoma" no longer exists; it is now "Astrocytoma, IDH-mutant, CNS WHO Grade 4".21

**Market Implication:** This bifurcation means that IDH sequencing (or specific IDH1 R132H IHC followed by sequencing if negative) is now a **prerequisite for naming the disease**. One cannot legally diagnose "Glioblastoma" in 2025 without knowing the IDH status. This creates a 100% penetration requirement for molecular testing in glioma diagnostics, expanding the market for sequencing reagents and interpretation software.

### **2.2 The Rise of "Molecular Glioblastoma" (Grade 4 by Decree)**

Perhaps the strongest validation of the expansion thesis is the introduction of molecular criteria that *override* histological grading. Historically, a tumor was only assigned Grade 4 (Glioblastoma) status if pathologists visually identified necrosis or microvascular proliferation (MVP). If a tumor lacked these aggressive features, it was designated Grade 2 or 3 (lower grade).

WHO 2021 introduces the concept of **"Diffuse Astrocytoma, IDH-wildtype with molecular features of Glioblastoma"**.26 A tumor can now be diagnosed as **Glioblastoma, IDH-wildtype, CNS WHO Grade 4** *even if it looks benign (Grade 2\) under the microscope*, provided it exhibits one of three specific molecular alterations 21:

1. **TERT promoter mutation:** A mutation in the promoter region of the telomerase reverse transcriptase gene, associated with aggressive clinical behavior.21  
2. **EGFR gene amplification:** A classic driver of glioblastoma proliferation.  
3. **Combined gain of whole chromosome 7 and loss of whole chromosome 10 (+7/-10):** A signature aneuploidy event in glioblastoma.

The "Upgrade" Phenomenon:  
This represents a massive shift in diagnostic logic. A patient previously told they had a "low-grade glioma" (Grade 2\) based on microscopy is now, upon molecular testing, reclassified as having Glioblastoma (Grade 4\) if a TERT mutation is found.

* **Impact:** This "molecular upgrade" changes the prognosis from years to months and radically alters the treatment plan, mandating immediate radiation and Temozolomide (Stupp protocol) rather than watchful waiting.30  
* **Validation of Complexity:** This creates a dangerous trap for centers without advanced diagnostics. A "visual-only" diagnosis is now potentially malpractice. The "Expansion" here is the expansion of **risk**. To mitigate this risk, health systems must adopt comprehensive molecular profiling for *all* diffuse gliomas, not just the obviously aggressive ones.

### **2.3 CDKN2A/B and the Grading of IDH-Mutant Tumors**

The complexity extends to the IDH-mutant (better prognosis) group. The WHO 2021 guidelines state that the presence of **CDKN2A/B homozygous deletion** in an IDH-mutant astrocytoma automatically elevates the tumor to **CNS WHO Grade 4**.24

This again overrides histology. A tumor might morphologically resemble a Grade 3 Anaplastic Astrocytoma, but if the software or sequencer detects the *CDKN2A* deletion, it must be treated as a Grade 4 malignancy. This creates a requirement for Copy Number Variation (CNV) analysis, which is often more technically demanding than simple mutation detection, further raising the barrier to entry for diagnostic labs and increasing the reliance on specialized interpretation tools.33

### **2.4 Diagnostic Drift in CNS and Data Normalization**

The reclassification has created significant "Diagnostic Drift" in survival statistics. By removing the IDH-mutant tumors (which generally have longer survival) from the "Glioblastoma" category, the survival statistics for "Glioblastoma" in 2025 will appear artificially worse than in 2015\. Conversely, by upgrading "low-grade" IDH-wildtype tumors (which are aggressive) to Glioblastoma, we are moving aggressive tumors out of the "low-grade" bucket, making the remaining low-grade bucket appear to have better survival statistics.30

Clinical Trial Chaos:  
This drift wreaks havoc on clinical trials and historical data comparisons. A trial recruiting "Glioblastoma" patients in 2018 would have included IDH-mutants. A trial in 2024 excludes them. Comparing results across this "WHO Divide" requires sophisticated data normalization—another function of the software infrastructure our thesis predicts. Platforms that can retrospectively reclassify patients based on their molecular data are essential for pharmaceutical companies attempting to leverage real-world evidence (RWE).35  
**Conclusion for Expansion Thesis (CNS):** The CNS paradigm shift proves that biology has conquered morphology. The diagnosis is no longer "what we see" but "what we sequence." This absolute dependence on molecular data (IDH, TERT, EGFR, CDKN2A) validates the need for an integrated diagnostic layer that sits above the pathologist's microscope, synthesizing genomic data to output the correct WHO diagnosis.

---

## **Section 3: The Operational Bottleneck – The Crisis of the Molecular Tumor Board**

The previous sections established the *biological* drivers of complexity (WHO reclassifications). This section analyzes the *operational* consequence: the systemic failure of traditional hospital workflows. The primary venue for managing this complexity is the **Molecular Tumor Board (MTB)**. Our analysis reveals that without software automation, the MTB is economically and operationally unsustainable.

### **3.1 The "Time Tax" of Precision Medicine**

<div className="time-tax-chart-container"></div>

An MTB is a multidisciplinary meeting where medical oncologists, pathologists, geneticists, bioinformaticians, and radiologists review complex cases to determine the optimal therapeutic path. While clinically considered the "gold standard" for complex cancer care, operationally it has become a crushing bottleneck.

Manual Preparation vs. Automation:  
Research indicates that manual preparation for an MTB is punishingly inefficient.

* **Preparation Time:** In traditional manual workflows, preparing a single patient case for MTB discussion takes approximately **3 to 4 hours** of aggregate staff time. This labor is distributed among nurse navigators, pathologists, and oncologists who must manually pull data from the Electronic Health Record (EHR), PDF pathology reports, third-party molecular lab portals (e.g., Foundation Medicine, Caris), and clinical trial databases.37  
* **The "Swivel Chair" Interface:** Clinicians are forced to toggle between disparate systems—Epic for clinical history, PACS for radiology images, LIS for pathology slides, and external web portals for genomic reports. This fragmentation, often referred to as the "swivel chair" interface, leads to cognitive fatigue, burnout, and a high risk of transcription errors.

Validation of Efficiency Gains:  
Software solutions (the "Infrastructure Expansion") demonstrate dramatic ROI by reducing this time tax.

* **Navify (Roche) Case Study:** The implementation of the Navify Tumor Board solution at the University of Missouri resulted in a **30% reduction** in preparation time across various cancer types. For the breast cancer tumor board specifically, nurse navigator preparation time plummeted by **69%**.39  
* **Discussion Efficiency:** Digital tools also streamline the meeting itself. Studies show that using a digital dashboard reduces the time needed to discuss a case by approximately **20-35%**, allowing boards to either review more patients in the same hour or discuss complex cases in greater depth without running overtime.41

### **3.2 The Financial Toxicity of the Tumor Board**

The "Expansion Thesis" is heavily supported by the financial unsustainability of manual MTBs. These meetings assemble the highest-paid professionals in the health system, creating a burn rate that is difficult to justify without high efficiency.

Cost Analysis:  
Using available salary data for Medical Oncologists ($380k), Pathologists ($318k), Radiologists ($428k), Surgeons ($584k), and support staff 43, the cost of simply convening the board is staggering.

* **Hourly Cost:** A single hour of an MTB with a full quorum of specialists costs approximately **$1,800 to $2,500** in direct physician compensation time.44  
* **Cost Per Case:** Discussing 6-10 cases per hour yields a cost of **$185 to $300 per patient** just for the meeting time, excluding the hours of preparation.44  
* **Total Burden:** A study at a single academic center estimated the annual cost of nine subspecialty tumor boards at **\~$800,000** in provider time alone.43

The ROI of Software:  
If software platforms like Syapse or GenomOncology can reduce preparation time by 30% and discussion time per case by 20%, the health system saves hundreds of thousands of dollars annually in "soft costs" (physician time).

* **University of Missouri Data:** The implementation of digital tumor board software resulted in an annual system-wide savings projection of **$299,614**, with a discounted payback period of just **0.17 years (approximately 2 months)**.40  
* **Australian Study:** A comprehensive study on the economics of precision oncology found that the cost per MTB recommendation was **$21,769** (AUD) when factoring in the high costs of sequencing, labor, and analysis.46 Reducing the labor component via automation is the only viable lever available to health systems to lower this cost structure.

### **3.3 The Cognitive Limit: Matching Clinical Trials**

The human brain cannot memorize the inclusion/exclusion criteria of thousands of active clinical trials, especially given the "Diagnostic Drift" where criteria change based on new WHO definitions (e.g., a trial now excluding IDH-mutant glioblastomas that previously accepted them).47

**The Match Rate Gap:**

* Manual matching rates for clinical trials in community settings historically hover around **3-5%** due to the complexity of criteria and the lack of time.  
* **Software-Assisted Matching:** Platforms like OncoLens and GenomOncology utilize Artificial Intelligence (AI) and Natural Language Processing (NLP) to screen unstructured pathology text against structured trial databases.  
  * **Case Study:** A community cancer center using OncoLens achieved a **350% increase** in genetic testing and trial identification by automating the screening process.49  
  * **Case Study:** The Pancreatic Cancer Action Network (PanCAN) increased its biomarker-driven trial matching capabilities by nearly **300%** using GenomOncology's API to structure and match patient data.50

**Conclusion for Expansion Thesis (Operational):** The complexity of molecular diagnostics has made the "manual" Tumor Board obsolete. The financial and temporal costs are too high. Health systems are forced to invest in software infrastructure not just for clinical quality, but for financial survival.

---

## **Section 4: The Digital Infrastructure Landscape – Validating the Solution**

The "Expansion Thesis" predicts that as diagnostic complexity expands, a new software vertical will emerge to contain it. The market evidence confirms this prediction. We are witnessing a consolidation of "Precision Oncology Platforms" that function as the operating system for cancer care, integrating EMR, LIS, and Molecular Data into a coherent view.

### **4.1 The Vendor Ecosystem**

The market has evolved beyond simple image viewers or document repositories to complex "Operating Systems for Oncology." The following analysis highlights key players validating the infrastructure demand.

#### **Roche Navify: The Workflow Automator**

Roche has aggressively moved into digital decision support with its Navify portfolio.

* **Core Proposition:** Navify focuses on the workflow efficiency of the tumor board, integrating directly with the EMR to pull patient data and presenting it in a dashboard.  
* **Validation:** The University of Missouri case study mentioned in Section 3 is the prime validation of this model. By saving $300k annually and reducing prep time by 30%, Navify proves that hospitals will pay for efficiency.39  
* **Strategy:** Roche uses Navify to defend its core diagnostic reagent business. By controlling the dashboard, they ensure their diagnostic data is front-and-center.

#### **GenomOncology: The Precision Engine**

GenomOncology (GO) focuses on the "heavy lifting" of genomic data interpretation.

* **Core Proposition:** Their "Precision Oncology Platform" (POP) acts as a high-speed translator, taking raw variant files (VCF) and converting them into clinically actionable reports with trial matches.  
* **Validation:** Their partnership with the **Glioblastoma Foundation** allowed the foundation to operationalize a genomic testing lab in just **two weeks**.51 This speed of deployment validates the "infrastructure as a service" model. Their work with **PanCAN** (300% increase in matches) proves the clinical utility of their matching algorithms.50  
* **Differentiation:** GO is vendor-agnostic, ingesting data from any sequencer or lab, making it the "Switzerland" of genomic data.

#### **Syapse: The Real-World Evidence Network**

Syapse focuses on the aggregation of data across health systems to create a "learning health system."

* **Core Proposition:** By pooling data from systems like **Intermountain Healthcare** and **Henry Ford Health**, Syapse allows clinicians to see "what happened to patients like mine."  
* **Validation:** At Intermountain, Syapse was the architectural foundation that enabled the system-wide rollout of precision oncology, proving that such a program is impossible without a dedicated software layer.52  
* **Business Model:** Syapse monetizes the aggregated, de-identified data by selling insights to Pharma, validating the "dual-sided" market model of these platforms.53

#### **OncoLens: The Community Connector**

OncoLens targets the fragmentation in community oncology, where most cancer patients are actually treated.

* **Core Proposition:** It automates the "triage" of patients for tumor boards and clinical trials, using AI to scan charts and identify candidates.  
* **Validation:** The **350% increase** in genetic testing at a community center 49 and the reduction of administrative time to **less than two hours** 54 demonstrate its impact on the resource-constrained community setting.

#### **GE HealthCare & MIM Software: Integrated Diagnostics**

In 2024, GE HealthCare acquired MIM Software, a leader in medical imaging analysis.55

* **Significance:** This acquisition signals the convergence of Radiology and Pathology ("Integrated Diagnostics"). MIM Software provides tools to overlay PET/CT images with dosimetric data and potentially molecular data. GE's move validates that major medtech incumbents view software as the key to unlocking value in their hardware install base.

### **4.2 Buying Centers and Market Adoption**

The purchase decision for this infrastructure has shifted. It is no longer just the Pathology Department buying a tool out of a discretionary budget.

* **The C-Suite Sale:** Because these platforms impact *clinical trial accrual* (a major revenue driver) and *physician efficiency* (a major cost driver), the buyer is now the Hospital Administration (CIO/CMO).37  
* **Community Expansion:** While academic centers were early adopters, the expansion is now moving to community oncology networks (e.g., Atrium Health, Intermountain). These networks handle 85% of cancer patients and lack the army of fellows to do manual prep. They *need* software to function.54  
* **Pharma as a Stakeholder:** Pharma companies are partnering with these platforms (e.g., Tempus, Syapse) to find rare patients. The fragmentation of lung cancer into rare subsets (*ROS1, RET, MET*) makes finding patients a "needle in a haystack" problem. Software that aggregates data across hospitals is valuable to Pharma for trial recruitment, creating a secondary revenue stream for the platforms.53

---

## **Section 5: Economic Implications and ROI**

The Expansion Thesis argues that precision oncology software is not a cost center, but a revenue enabler and cost container.

### **5.1 The Return on Precision**

A landmark study led by Queen's University Belfast provides the macro-economic validation for the expansion thesis. The study found that a **Precision Oncology** approach (using companion diagnostics to guide treatment) cut the R\&D cost of developing a new cancer drug by over **$1 billion** compared to the "one size fits all" approach.59 This efficiency at the Pharma level trickles down to the provider level; using biomarkers to select therapy avoids the waste of expensive drugs on patients who will not respond.

### **5.2 Reimbursement and "Diagnostic Drift"**

Diagnostic drift has financial consequences. As "low-grade" tumors are reclassified as high-grade (CNS) or specific subtypes (Lung), reimbursement codes change.

* **Billing Specificity:** Payers increasingly require specific molecular codes for reimbursement. A generic "Lung Cancer" code may not justify the use of a $15,000/month targeted therapy. Reclassifying an "LCC" to an "Adenocarcinoma, EGFR+" unlocks the reimbursement for the drug.  
* **The Cost of "NOS":** Conversely, a diagnosis of "NOS" leaves money on the table. It often leads to the use of cheaper, less effective generic chemotherapy, but may result in higher downstream costs due to faster progression and hospitalization.

### **5.3 Integrated Diagnostics: The Final Frontier**

The future of the expansion thesis lies in **Integrated Diagnostics**—the fusion of Radiology and Pathology.

* **Radiogenomics:** Using AI on MRI scans to predict molecular status (e.g., predicting IDH mutation in glioma before biopsy).60  
* **Operational Fusion:** Combined reporting systems where the Radiologist and Pathologist issue a single, unified diagnostic report. This reduces "diagnostic uncertainty" and is highly valued by treating oncologists.62

---

## **Section 6: Conclusion**

The research unequivocally validates the "Expansion Thesis" through three converging lines of evidence:

1. **The Complexity is Irreversible (Biological Validation):** The WHO 2021 classifications for Lung and CNS tumors have dismantled the old, simple morphological categories. By mandating molecular definitions (e.g., *TERT* promoter mutations for Glioblastoma, broad IHC/NGS panels for Lung), the global medical community has codified complexity into law. There is no going back to H\&E.  
2. **The Manual Workflow is Broken (Operational Validation):** The financial analysis of Molecular Tumor Boards demonstrates that manual curation of this complexity is economically toxic to health systems. The "Time Tax" of 3-4 hours per case is unsustainable in a labor-constrained healthcare environment.  
3. **Software is the Only Bridge (Market Validation):** The "Expansion" of the diagnostic funnel (more biomarkers, more subtypes, more data) has outpaced human cognitive capacity. Enterprise-grade software infrastructure (Navify, Syapse, GenomOncology) is no longer a luxury "academic" tool; it is the essential operating system required to deliver standard-of-care medicine without bankrupting the provider.

**Final Verdict:** The "Expansion" is real. It is driven by biology, codified by the WHO, and currently unmanaged by legacy infrastructure. This creates a prime investment window for platforms that can automate the ingestion, interpretation, and clinical application of complex diagnostic data.

---

### **Appendix: Key Data Tables**

#### **Table 1: WHO 2021 Lung Cancer Reclassification Impact**

| Legacy Diagnosis | WHO 2021 Status | Required Action | Outcome |
| :---- | :---- | :---- | :---- |
| **Large Cell Carcinoma (LCC)** | "Diagnosis of Exclusion" (Resection Only) | Mandatory IHC (TTF-1, p40) | \~90% Reclassified as Adeno or Squamous 1 |
| **Squamous Cell Carcinoma** | Subtyped | IHC (p40 positive) | Separates from "Basaloid" variants; confirms non-keratinizing types 6 |
| **NSCLC-NOS** | Operational Term Only | IHC \+ Molecular Profiling | "Tissue Stewardship" crisis; prioritized for NGS 4 |
| **Small Biopsy** | Distinct Classification | Minimal IHC (2-marker panel) | Preserve tissue for *EGFR/ALK/ROS1* testing 3 |

#### **Table 2: WHO 2021 CNS "Molecular Glioblastoma" Criteria**

| Histological Appearance | Molecular Marker | WHO 2021 Diagnosis | Clinical Impact |
| :---- | :---- | :---- | :---- |
| Diffuse Astrocytoma (Grade 2/3) | **IDH-Wildtype** \+ **TERT Mutation** | **Glioblastoma, IDH-WT, Grade 4** | Immediate aggressive Chemo/Rad (Stupp Protocol) 21 |
| Diffuse Astrocytoma (Grade 2/3) | **IDH-Wildtype** \+ **EGFR Amp** | **Glioblastoma, IDH-WT, Grade 4** | Reclassification from "Low Grade" to highest malignancy |
| Diffuse Astrocytoma (Grade 2/3) | **IDH-Wildtype** \+ **\+7/-10** | **Glioblastoma, IDH-WT, Grade 4** | "Molecular Upgrade" overriding histology |
| Glioblastoma (Necrosis present) | **IDH-Mutant** | **Astrocytoma, IDH-Mutant, Grade 4** | No longer called "Glioblastoma"; distinct prognosis 21 |

#### **Table 3: Economic Impact of Molecular Tumor Board (MTB) Automation**

| Metric | Manual Process | Software-Augmented | ROI / Savings |
| :---- | :---- | :---- | :---- |
| **Prep Time (Nurse/Path)** | \~3-4 Hours/Case | \~1-2 Hours/Case | **69% Reduction** (Breast TB, Missouri) 39 |
| **Cost Per Case (Physician Time)** | \~$185 \- $300 | Reduced by \~30% | **$300k/Year** savings (Univ. Missouri) 40 |
| **Trial Matching** | 3-5% Match Rate | \>10-15% Match Rate | **300-350% Increase** in identifications (OncoLens/GenomOncology) 49 |
| **Report Generation** | Manual Word/PDF | Automated (API) | Operational in 2 weeks vs. Months (GenomOncology) 51 |

#### **Works cited**

1. The 2015 World Health Organization Classification of Lung Tumors: Impact of Genetic, Clinical and Radiologic Advances Since the 2004 Classification \- PubMed, accessed on November 26, 2025, [https://pubmed.ncbi.nlm.nih.gov/26291008/](https://pubmed.ncbi.nlm.nih.gov/26291008/)  
2. 2021 WHO Classification of Lung Cancer: Molecular Biology Research and Radiologic-Pathologic Correlation \- PubMed, accessed on November 26, 2025, [https://pubmed.ncbi.nlm.nih.gov/38358935/](https://pubmed.ncbi.nlm.nih.gov/38358935/)  
3. An Update on the Classification of Lung and Pleural Tumors \- Xia & He Publishing Inc., accessed on November 26, 2025, [https://www.xiahepublishing.com/2771-165X/JCTP-2023-00008](https://www.xiahepublishing.com/2771-165X/JCTP-2023-00008)  
4. An Update on WHO Classification of Thoracic Tumours 2021- Newly Described Entities and Terminologies \- JCDR, accessed on November 26, 2025, [https://www.jcdr.net/articles/PDF/18076/62583\_CE\[Ra1\]\_F(IS)\_PF1(HB\_SHU\_KM)\_PFA(HB\_KM)\_PN(KM).pdf](https://www.jcdr.net/articles/PDF/18076/62583_CE[Ra1]_F\(IS\)_PF1\(HB_SHU_KM\)_PFA\(HB_KM\)_PN\(KM\).pdf)  
5. Impact of Recent Developments in Lung Cancer on the Practice of Pathology \- Allen Press, accessed on November 26, 2025, [https://meridian.allenpress.com/aplm/article/140/4/322/65178/Impact-of-Recent-Developments-in-Lung-Cancer-on](https://meridian.allenpress.com/aplm/article/140/4/322/65178/Impact-of-Recent-Developments-in-Lung-Cancer-on)  
6. Update on Immunohistochemistry for the Diagnosis of Lung Cancer \- MDPI, accessed on November 26, 2025, [https://www.mdpi.com/2072-6694/10/3/72](https://www.mdpi.com/2072-6694/10/3/72)  
7. Reevaluation and reclassification of resected lung carcinomas originally diagnosed as squamous cell carcinoma using immunohistochemical analysis \- PubMed, accessed on November 26, 2025, [https://pubmed.ncbi.nlm.nih.gov/25871623/](https://pubmed.ncbi.nlm.nih.gov/25871623/)  
8. Next-Generation Sequencing of a Cohort of Pulmonary Large Cell Carcinomas Reclassified by World Health Organization 2015 Criteria \- Allen Press, accessed on November 26, 2025, [https://meridian.allenpress.com/aplm/article/140/4/312/65209/Next-Generation-Sequencing-of-a-Cohort-of](https://meridian.allenpress.com/aplm/article/140/4/312/65209/Next-Generation-Sequencing-of-a-Cohort-of)  
9. Pulmonary large cell carcinoma with neuroendocrine morphology shows genetic similarity to large cell neuroendocrine carcinoma \- PMC \- PubMed Central, accessed on November 26, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC8832809/](https://pmc.ncbi.nlm.nih.gov/articles/PMC8832809/)  
10. Molecular Pathology of Non–Small Cell Lung Cancer A Practical Guide, accessed on November 26, 2025, [https://academic.oup.com/ajcp/article-pdf/138/3/332/24993021/ajcpath138-0332.pdf](https://academic.oup.com/ajcp/article-pdf/138/3/332/24993021/ajcpath138-0332.pdf)  
11. Lung cancer histology-driven strategic therapeutic approaches \- Galli \- Shanghai Chest, accessed on November 26, 2025, [https://shc.amegroups.org/article/view/5774/html](https://shc.amegroups.org/article/view/5774/html)  
12. Unravelling the diagnostic pathology and molecular biomarkers in lung cancer, accessed on November 26, 2025, [https://publications.ersnet.org/content/breathe/20/2/230192](https://publications.ersnet.org/content/breathe/20/2/230192)  
13. New update to the guidelines on testing predictive biomarkers in non-small-cell lung cancer, accessed on November 26, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC10119050/](https://pmc.ncbi.nlm.nih.gov/articles/PMC10119050/)  
14. Molecular Diagnostic and Precision Medicine in Non-Small Cell Lung Cancer. An Update on the Treatment of the Most Important Actionable Oncogenic Driver Alterations \- healthbook TIMES Oncology Hematology, accessed on November 26, 2025, [https://onco-hema.healthbooktimes.org/article/24805-molecular-diagnostic-and-precision-medicine-in-non-small-cell-lung-cancer-an-update-on-the-treatment-of-the-most-important-actionable-oncogenic-drive](https://onco-hema.healthbooktimes.org/article/24805-molecular-diagnostic-and-precision-medicine-in-non-small-cell-lung-cancer-an-update-on-the-treatment-of-the-most-important-actionable-oncogenic-drive)  
15. Molecular Solid Tumor Algorithm – Simplified Patient-Centric/Cost-Effective Approach by Pathologists | American Journal of Clinical Pathology | Oxford Academic, accessed on November 26, 2025, [https://academic.oup.com/ajcp/article/158/Supplement\_1/S141/6815238](https://academic.oup.com/ajcp/article/158/Supplement_1/S141/6815238)  
16. Current challenges and practical aspects of molecular pathology for non-small cell lung cancers \- PMC, accessed on November 26, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC10948551/](https://pmc.ncbi.nlm.nih.gov/articles/PMC10948551/)  
17. Expert recommendations for treating metastatic non-small cell lung cancer, accessed on November 26, 2025, [https://www.fredhutch.org/en/news/blog/2023/01/expert-recommendations-for-treating-metastatic-nonsmall-cell-lung-cancer.html](https://www.fredhutch.org/en/news/blog/2023/01/expert-recommendations-for-treating-metastatic-nonsmall-cell-lung-cancer.html)  
18. Refining treatment strategies for non-small cell lung cancer lacking actionable mutations: insights from multi-omics studies \- PMC \- PubMed Central, accessed on November 26, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC12603130/](https://pmc.ncbi.nlm.nih.gov/articles/PMC12603130/)  
19. WHO classification of thoracic tumors | Radiology Reference Article | Radiopaedia.org, accessed on November 26, 2025, [https://radiopaedia.org/articles/who-classification-of-thoracic-tumours](https://radiopaedia.org/articles/who-classification-of-thoracic-tumours)  
20. The New WHO Classification of Lung Tumors, accessed on November 26, 2025, [https://www.ilcn.org/the-new-who-classification-of-lung-tumors/](https://www.ilcn.org/the-new-who-classification-of-lung-tumors/)  
21. Updates in Glioma and Meningioma Classification – WHO 2021 & New Entities in the Literature \- College of American Pathologists, accessed on November 26, 2025, [https://www.cap.org/member-resources/articles/updates-in-glioma-and-meningioma-classification-who-2021-new-entities-in-the-literature](https://www.cap.org/member-resources/articles/updates-in-glioma-and-meningioma-classification-who-2021-new-entities-in-the-literature)  
22. The WHO 2021 Classification of Central Nervous System tumours: a practical update on what neurosurgeons need to know—a minireview \- PMC, accessed on November 26, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC9427889/](https://pmc.ncbi.nlm.nih.gov/articles/PMC9427889/)  
23. The 2021 World Health Organization Central Nervous System Tumor Classification: The Spectrum of Diffuse Gliomas, accessed on November 26, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC11202067/](https://pmc.ncbi.nlm.nih.gov/articles/PMC11202067/)  
24. What You Need to Know About the New Updates to Brain Tumor Classifications and Grades, accessed on November 26, 2025, [https://braintumor.org/news/what-you-need-to-know-about-the-new-updates-to-brain-tumor-classifications-and-grades/](https://braintumor.org/news/what-you-need-to-know-about-the-new-updates-to-brain-tumor-classifications-and-grades/)  
25. Clinical features, MRI, molecular alternations, and prognosis of astrocytoma based on WHO 2021 classification of central nervous system tumors: A single‐center retrospective study, accessed on November 26, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC11226410/](https://pmc.ncbi.nlm.nih.gov/articles/PMC11226410/)  
26. The 2021 World Health Organization Classification of Tumors of the Central Nervous System: What Neuroradiologists Need to Know | American Journal of Neuroradiology, accessed on November 26, 2025, [https://www.ajnr.org/content/43/7/928](https://www.ajnr.org/content/43/7/928)  
27. cIMPACT-NOW update 3: recommended diagnostic criteria for "Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV" \- PubMed, accessed on November 26, 2025, [https://pubmed.ncbi.nlm.nih.gov/30259105/](https://pubmed.ncbi.nlm.nih.gov/30259105/)  
28. Glioblastoma, IDH-wildtype | Radiology Reference Article | Radiopaedia.org, accessed on November 26, 2025, [https://radiopaedia.org/articles/glioblastoma-idh-wildtype](https://radiopaedia.org/articles/glioblastoma-idh-wildtype)  
29. Prognostic Impact of TERT Promoter Mutations in Adult-Type Diffuse Gliomas Based on WHO2021 Criteria \- MDPI, accessed on November 26, 2025, [https://www.mdpi.com/2072-6694/16/11/2032](https://www.mdpi.com/2072-6694/16/11/2032)  
30. IDH-wildtype lower-grade diffuse gliomas: the importance of histological grade and molecular assessment for prognostic stratification \- PubMed Central, accessed on November 26, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC8168809/](https://pmc.ncbi.nlm.nih.gov/articles/PMC8168809/)  
31. Molecular GBM versus Histopathological GBM: Radiology-Pathology- Genetic Correlation and the New WHO 2021 Definition of Glioblastoma \- American Journal of Neuroradiology, accessed on November 26, 2025, [https://www.ajnr.org/highwire/filestream/109747/field\_highwire\_adjunct\_files/0/ajnr.A8225.full.pdf](https://www.ajnr.org/highwire/filestream/109747/field_highwire_adjunct_files/0/ajnr.A8225.full.pdf)  
32. Clinical updates on gliomas and implications of the 5th edition of the WHO classification of central nervous system tumors \- Frontiers, accessed on November 26, 2025, [https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2023.1131642/full](https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2023.1131642/full)  
33. What's new in neuropathology 2024: CNS WHO 5th edition updates \- PubMed Central, accessed on November 26, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC11573473/](https://pmc.ncbi.nlm.nih.gov/articles/PMC11573473/)  
34. Histological and molecular glioblastoma, IDH-wildtype: a real-world landscape using the 2021 WHO classification of central nervous system tumors, accessed on November 26, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC10358772/](https://pmc.ncbi.nlm.nih.gov/articles/PMC10358772/)  
35. Major Changes in 2021 World Health Organization Classification of Central Nervous System Tumors | RadioGraphics \- RSNA Journals, accessed on November 26, 2025, [https://pubs.rsna.org/doi/abs/10.1148/rg.210236](https://pubs.rsna.org/doi/abs/10.1148/rg.210236)  
36. Clinical implications of the 2021 edition of the WHO classification of central nervous system tumours \- PubMed, accessed on November 26, 2025, [https://pubmed.ncbi.nlm.nih.gov/35729337/](https://pubmed.ncbi.nlm.nih.gov/35729337/)  
37. Establishment of a virtual expert network for molecular tumor boards \- Roche, accessed on November 26, 2025, [https://assets.cwp.roche.com/f/94122/5cf221dd66/roche-healthcare-consulting-molecular-tumor-board-whitepaper.pdf](https://assets.cwp.roche.com/f/94122/5cf221dd66/roche-healthcare-consulting-molecular-tumor-board-whitepaper.pdf)  
38. Digital Tumor Board Solutions Have Significant Impact on Case Preparation | JCO Clinical Cancer Informatics \- ASCO Publications, accessed on November 26, 2025, [https://ascopubs.org/doi/10.1200/CCI.20.00029](https://ascopubs.org/doi/10.1200/CCI.20.00029)  
39. Novel Digital Dashboard Improves Cancer Case Review Efficiency \- MU School of Medicine, accessed on November 26, 2025, [https://medicine.missouri.edu/news/novel-digital-dashboard-improves-cancer-case-review-efficiency](https://medicine.missouri.edu/news/novel-digital-dashboard-improves-cancer-case-review-efficiency)  
40. Economic impact of digital tumor board software: An evaluation of cost savings using real-world data. \- ASCO Publications, accessed on November 26, 2025, [https://ascopubs.org/doi/10.1200/JCO.2022.40.16\_suppl.e18794](https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.e18794)  
41. The Use of an Integrated Digital Tool to Improve the Efficiency of Multidisciplinary Tumor Boards-A Prospective Trial in Taiwan \- PubMed, accessed on November 26, 2025, [https://pubmed.ncbi.nlm.nih.gov/39941815/](https://pubmed.ncbi.nlm.nih.gov/39941815/)  
42. The Use of an Integrated Digital Tool to Improve the Efficiency of Multidisciplinary Tumor Boards—A Prospective Trial in Taiwan \- NIH, accessed on November 26, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC11815928/](https://pmc.ncbi.nlm.nih.gov/articles/PMC11815928/)  
43. Multidisciplinary tumor boards present technical and financial challenges in the COVID-19 era \- PubMed Central, accessed on November 26, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC8010380/](https://pmc.ncbi.nlm.nih.gov/articles/PMC8010380/)  
44. NCOG-75. ESTIMATED PHYSICIAN COST OF A NEURO-ONCOLOGY MULTIDISCIPLINARY TEAM (MDT) TUMOR BOARD MEETING AT A SINGLE ACADEMIC CENTER \- NIH, accessed on November 26, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC7651181/](https://pmc.ncbi.nlm.nih.gov/articles/PMC7651181/)  
45. NCOG-75. ESTIMATED PHYSICIAN COST OF A NEURO-ONCOLOGY MULTIDISCIPLINARY TEAM (MDT) TUMOR BOARD MEETING AT A SINGLE ACADEMIC CENTER, accessed on November 26, 2025, [https://academic.oup.com/neuro-oncology/article/22/Supplement\_2/ii146/5961071](https://academic.oup.com/neuro-oncology/article/22/Supplement_2/ii146/5961071)  
46. The economic costs of precision medicine for clinical translational ..., accessed on November 26, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC11452525/](https://pmc.ncbi.nlm.nih.gov/articles/PMC11452525/)  
47. Effect of sponsor on enrollment criteria in non-small cell lung cancer clinical trials, accessed on November 26, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC10226152/](https://pmc.ncbi.nlm.nih.gov/articles/PMC10226152/)  
48. Impact of broadening clinical trial eligibility criteria for advanced non-small cell lung cancer patients: Real-world analysis. \- ASCO Publications, accessed on November 26, 2025, [https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.18\_suppl.LBA108](https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.18_suppl.LBA108)  
49. OncoLens Analytics Enables a 350% Increase in Genetic Testing at Community Cancer Center, accessed on November 26, 2025, [https://www.oncolens.com/casestudy/oncolens-analytics-enables-a-350-increase-in-genetic-testing-at-community-cancer-center/](https://www.oncolens.com/casestudy/oncolens-analytics-enables-a-350-increase-in-genetic-testing-at-community-cancer-center/)  
50. GO Case Studies — Precision Oncology Solutions \- GenomOncology, accessed on November 26, 2025, [https://genomoncology.com/go-case-studies/](https://genomoncology.com/go-case-studies/)  
51. GenomOncology Technology Enables Rapid Launch of Glioblastoma Foundation Genomic Testing Lab \- BioPharma BoardRoom, accessed on November 26, 2025, [https://www.biopharmaboardroom.com/news/17/3998/genomoncology-technology-enables-rapid-launch-of-glioblastoma-foundation-genomic-testing-lab.html](https://www.biopharmaboardroom.com/news/17/3998/genomoncology-technology-enables-rapid-launch-of-glioblastoma-foundation-genomic-testing-lab.html)  
52. Syapse Intermountain Case Study v2.2, accessed on November 26, 2025, [https://www.georgiacancerinfo.org/images/public/embedded/Syapse%20Intermountain%20Case%20Study.pdf](https://www.georgiacancerinfo.org/images/public/embedded/Syapse%20Intermountain%20Case%20Study.pdf)  
53. Tempus | AI-enabled precision medicine, accessed on November 26, 2025, [https://www.tempus.com/](https://www.tempus.com/)  
54. Process improvement and cost savings in cancer care through the utilization of technology in tumor boards. \- ASCO Publications, accessed on November 26, 2025, [https://ascopubs.org/doi/10.1200/JCO.2018.36.15\_suppl.e18779](https://ascopubs.org/doi/10.1200/JCO.2018.36.15_suppl.e18779)  
55. GE HealthCare Acquires MIM Software, Enhancing Precision Care, accessed on November 26, 2025, [https://sliceofhealthcare.com/ge-healthcare-acquires-mim-software-enhancing-precision-care/](https://sliceofhealthcare.com/ge-healthcare-acquires-mim-software-enhancing-precision-care/)  
56. GE HealthCare announces agreement to acquire MIM Software, accessed on November 26, 2025, [https://www.gehealthcare.com/about/newsroom/press-releases/ge-healthcare-announces-agreement-to-acquire-mim-software](https://www.gehealthcare.com/about/newsroom/press-releases/ge-healthcare-announces-agreement-to-acquire-mim-software)  
57. GE HealthCare acquires medical imaging software developer \- Becker's ASC, accessed on November 26, 2025, [https://www.beckersasc.com/asc-transactions-and-valuation-issues/ge-healthcare-acquires-medical-imaging-software-developer/](https://www.beckersasc.com/asc-transactions-and-valuation-issues/ge-healthcare-acquires-medical-imaging-software-developer/)  
58. (PDF) Delivering the precision oncology paradigm: reduced R\&D costs and greater return on investment through a companion diagnostic informed precision oncology medicines approach \- ResearchGate, accessed on November 26, 2025, [https://www.researchgate.net/publication/372153849\_Delivering\_the\_precision\_oncology\_paradigm\_reduced\_RD\_costs\_and\_greater\_return\_on\_investment\_through\_a\_companion\_diagnostic\_informed\_precision\_oncology\_medicines\_approach](https://www.researchgate.net/publication/372153849_Delivering_the_precision_oncology_paradigm_reduced_RD_costs_and_greater_return_on_investment_through_a_companion_diagnostic_informed_precision_oncology_medicines_approach)  
59. Landmark study demonstrates economic benefit of precision medicine in treating cancer | News | Queen's University Belfast, accessed on November 26, 2025, [https://www.qub.ac.uk/News/Allnews/2023/landmark-study-economic-benefit-precision-medicine-treating-cancer.html](https://www.qub.ac.uk/News/Allnews/2023/landmark-study-economic-benefit-precision-medicine-treating-cancer.html)  
60. Updates in IDH-Wildtype Glioblastoma \- PMC \- PubMed Central \- NIH, accessed on November 26, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC9154038/](https://pmc.ncbi.nlm.nih.gov/articles/PMC9154038/)  
61. Definition of Glioblastoma Correlation and the New WHO 2021 GBM \- American Journal of Neuroradiology, accessed on November 26, 2025, [https://www.ajnr.org/content/ajnr/early/2024/07/11/ajnr.A8225.full.pdf](https://www.ajnr.org/content/ajnr/early/2024/07/11/ajnr.A8225.full.pdf)  
62. Administrative Alignment for Integrated Diagnostics Leads to Shortened Time to Diagnose and Service Optimization | Request PDF \- ResearchGate, accessed on November 26, 2025, [https://www.researchgate.net/publication/382693533\_Administrative\_Alignment\_for\_Integrated\_Diagnostics\_Leads\_to\_Shortened\_Time\_to\_Diagnose\_and\_Service\_Optimization](https://www.researchgate.net/publication/382693533_Administrative_Alignment_for_Integrated_Diagnostics_Leads_to_Shortened_Time_to_Diagnose_and_Service_Optimization)  
63. Integrating AP and radiology, inch by inch \- CAP TODAY, accessed on November 26, 2025, [https://www.captodayonline.com/integrating-ap-radiology-inch-inch/?print=print](https://www.captodayonline.com/integrating-ap-radiology-inch-inch/?print=print)